

FOI 3375

20th October 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs?

Response:

Current patients as of 09/10/2025

Adalimumab – Humira	7
Adalimumab Biosimilar	190
Etrasimod	0
Filgotinib	0
Golimumab	<5
Infliximab – Remicade	0
Infliximab Biosimilar	115
Mirikizumab	<5
Ozanimod	0
Risankizumab	<5
Tofacitinib	<5
Upadacitinib	38
Ustekinumab – Stelara	12
Ustekinumab Biosimilar	93
Vedolizumab	113

Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs?

Response:

Adalimumab – Humira	6
Adalimumab Biosimilars	126
Golimumab	0
Infliximab – Remicade	0
Infliximab Biosimilars	56
Risankizumab	<5
Upadacitinib	19
Ustekinumab – Stelara	8
Ustekinumab Biosimilar	61
Vedolizumab	53
Mirikizumab	0

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net